RecruitingPhase 2NCT07505745

MOTS-c for Improving Insulin Sensitivity in Adults With Prediabetes and Overweight/Obesity

A Phase 2a, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacodynamics of MOTS-c (a Mitochondrial-Derived Peptide) in Adults With Prediabetes and Overweight/Obesity

Sponsor

Hudson Biotech

Enrollment

120 participants

Start Date

Feb 2, 2026

Study Type

INTERVENTIONAL

Conditions

Insulin Resistance Prediabetes Overweight/Obesity

Summary

This Phase 2a study evaluates whether 12 weeks of treatment with investigational MOTS-c improves insulin sensitivity compared with placebo in adults with prediabetes and overweight/obesity. Participants are randomized 1:1 to MOTS-c or placebo, receive standardized lifestyle counseling, and are followed for safety through Week 16.

Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called MOTS-c (MDP), a drug called Placebo, and others for people with insulin resistance, overweight/obesity, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.